Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir in Hospitalized Children With RSV Infection
CTR20212296Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilematovir in respiratory syncytial virus disease (RSV), sponsored by Janssen Pharmaceutical. Started Sep 2021; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20212296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212296.